Abstract

A cancer phenotype is driven by several proteins and targeting a cluster of functionally interdependent molecules should be more effective for therapeutic intervention. This is specifically important for Ras-dependent cancer, as mutated (MT) Ras is non-druggable and targeting its interaction with effectors may be essential for therapeutic intervention. Here, we report that a protein-complex activated by the Ras effector p38γ MAPK is a novel therapeutic target for K-Ras-dependent colon cancer. Unbiased proteomic screening and immune-precipitation analyses identified p38γ interaction with heat shock protein 90 (Hsp90) and K-Ras in K-Ras MT, but not wild-type (WT), colon cancer cells, indicating a role of this complex in Ras-dependent growth. Further experiments showed that this complex requires p38γ and Hsp90 activity to maintain MT, but not WT, K-Ras protein expression. Additional studies demonstrated that this complex is activated by p38γ-induced Hsp90 phosphorylation at S595, which is important for MT K-Ras stability and for K-Ras dependent growth. Of most important, pharmacologically inhibition of Hsp90 or p38γ activity disrupts the complex, decreases K-Ras expression, and selectively inhibits the growth of K-Ras MT colon cancer in vitro and in vivo. These results demonstrated that the p38γ-activated ternary complex is a novel therapeutic target for K-Ras-dependent colon cancer.

Highlights

  • Mutated (MT) K-Ras is the most established oncogene in human cancer, which occurs in up to 50% of colon cancer [1, 2]

  • Because levels of p-p38γ protein expression are associated with those of its substrate protein tyrosine phosphatase H1 phosphorylation (p-PTPH1) in K-Ras MT, but not WT, colon cancer cells [22], we examined if p38γ may phosphorylate heat shock protein 90 (Hsp90) thereby increasing its chaperone activity toward MT K-Ras

  • Our studies provide several pieces of evidence that together indicate that a p38γ-activated ternary-complex with Hsp90 and K-Ras may be a novel therapeutic target for K-Ras dependent colon cancer

Read more

Summary

INTRODUCTION

Mutated (MT) K-Ras is the most established oncogene in human cancer, which occurs in up to 50% of colon cancer [1, 2]. We recently showed that p38γ binds and phosphorylates several proteins important for cancer growth and progression including protein tyrosine phosphatase H1 (PTPH1) [22], DNA topoisomerase IIα [29], and estrogen receptor [24] These results indicate that p38γ may promote the malignant growth through interacting and phosphorylating its substrates. Our results showed that p38γ forms a complex with Hsp and K-Ras in K-Ras MT colon cancer cells through activating Hsp by phosphorylation Disrupting of this ternarycomplex by targeting Hsp or p38γ decreases MT K-Ras expression and selectively inhibits K-Ras dependent colon cancer growth in vitro and/or in vivo. These results demonstrated that a ternary protein-complex activated by the Ras effector p38γ is a therapeutic target for K-Ras dependent colon cancer

RESULTS
DISCUSSION
MATERIALS AND METHODS
Downward J
10. Blagosklonny MV
37. Blagosklonny MV
Findings
53. Blagosklonny MV
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call